

05/01/98
JCS95 U.S. PTO

GP 1614 #11
Attorney Docket No. 205.7
PATENT 5/16/98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Choung Kim

Serial No.: 08/735,385

Group No.: 1614

Filed: October 21, 1996

Examiner: K. Weddington

For: PIPERIDINE COMPOUNDS

RECEIVED

MAY 8 1998

Assistant Commissioner for Patents

Washington, D.C. 20231

MAIL ROOM
SERVICE CENTER

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE
MAILING DATE OF EITHER A FINAL ACTION OR NOTICE
OF ALLOWANCE (37 CFR 1.97 (c))

TIME TRANSMITTAL OF ACCOMPANYING INFORMATION
DISCLOSURE STATEMENT

1. The information disclosure statement transmitted herewith is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

(1) a final action under § 1.113 or

(2) a notice of allowance under § 1.311,

whichever occurs first.

CERTIFICATE OF MAILING (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Robin Torres

(Type or print name of person mailing paper)

Robin Torres

(Signature of person mailing paper)

05/04/1998 SLUANG 00000085 071250 08735385

01 FC:126

Date:

240.00 CH

April 29, 1998

CERTIFICATION OR FEE

2. Accompany this transmittal is

A. ☐ a certification as specified in 37 CFR 1.97 (e)

OR

B. ☒ the fee set forth in 37 CFR 1.17 (p) for submission of an information disclosure statement under § 1.97 (c). (\$240.00).

FEE PAYMENT

3. Applicant elects the option to pay the fee set forth in 37 CFR 1.17 (p) for submission of an information disclosure statement under § 1.97 (c). (\$240.00).

Fee due \$ 240.00

METHOD OF PAYMENT OF FEE

4.

☐ attached is check in the sum of \$ _____

☒ charge Account No. 07-1250 the sum of \$ 240.00

A duplicate of this request is attached.

If any additional fees are due, please charge Account No. 07-1250

Reg. No. 35,071

Tel. No.: (650) 572-6569



SIGNATURE OF ATTORNEY

Mark L. Bosse
Type or print name of attorney

Gilead Sciences, Inc.
333 Lakeside Drive
P.O. Address

Foster City, CA 94404

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Choung Kim

Serial No.: 08/735,385

Group No.: 1614

Filed: October 21, 1996

Examiner: K. Weddington

For: PIPERIDINE COMPOUNDS

Assistant Commissioner for Patents

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT (modified)

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ FORM PTO - 1449 (Modified)
3. ☒ Copies of Listed Information Items Accompanying This Statement

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Robin Torres

(Type or print name of person mailing paper)

Date: April 29, 1998

Robin Torres
(Signature of person mailing paper)



Section 3. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Reg. No. 35,071



SIGNATURE OF ATTORNEY

Tel. No.: (650) 572-6569

Mark L. Bosse

Type or print name of attorney

Gilead Sciences, Inc.

333 Lakeside Drive

P.O. Address

Foster City, CA 94404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.: 205.7

SERIAL NO.: 08/735,385

APPLICANT: Kim, Choung

FILING DATE: 10/21/96

GROUP ART UNIT:

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	ISSUE DATE	PATENTEE	CLASS/ SUBCLASS	FILING DATE
	5,428,073	6/27/95	Kunisch et al.		10/5/92
	5,622,916	4/22/97	Kunisch et al.		9/15/93

FOREIGN PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	PUBLICATION DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES/NO
	0 539 204 A1	10/22/92	EUROPE		
	WO 92/06691	4/30/92	PCT		
	WO 96/26933	9/6/96	PCT		

OTHER DOCUMENTS

EXAMR'S INITIALS	ARTICLE
	Kudo, et al., "Syntheses and Activities of N-Substituted Derivatives of Siastatin B", 45(10):1662-1668, THE JOURNAL OF ANTIBIOTICS, October 1992
	Microbial Chem Res Found, "Siastatin B Derivative as Novel Antiviral Substance and its Production", Publication No. 04089481, Patent Abstracts of Japan, March 23, 1992
	Nishimura et al., "The First L-Iduronic Acid-Type 1-N-Iminosugars Having Inhibitory Activity of Experimental Metastasis", 118:3051-3052, J AM CHEM SOC, 1996
	Nishimura et al., "Totally Synthetic Analogues of Siastatin B. III. Trifluoroacetamide Analogues Having Inhibitory Activity for Tumor Metastasis", 47(1):101-107, THE JOURNAL OF ANTIBIOTICS, January 1994
	Nishimura, et al., "Potent Inhibition of Neuraminidase by N-(1,2-Dihydroxypropyl) Derivatives of Siastatin B and its Analogs", 1(1):33-38, NATURAL PRODUCT LETTERS, 1992

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.